Cross-Sector entity
Serum Institute of India is most often covered alongside Africa Centres for Disease Control and Prevention, which appears in 1 of these 2 stories. Across a 36-day span, the pace is roughly 0.4 stories per week. The clearest coverage concentration is pharma: 1 of 2 stories, with the rest divided among 1 other category.
2 verified stories tracked
Last mentioned: 22h ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Serum Institute of India is most often covered alongside Africa Centres for Disease Control and Prevention, which appears in 1 of these 2 stories. Across a 36-day span, the pace is roughly 0.4 stories per week. The clearest coverage concentration is pharma: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 2 original sources each. We currently track 2 Cross-Sector stories that mention Serum Institute of India, published between July 20, 2026 and August 24, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Serum Institute of India. Shared-story counts are live from our verified record — not editorial picks.
First-in-Human Trial Begins
A Phase 1 clinical trial of the ChAdOx1-biEBOV vaccine, enrolling 50 healthy adults, commences with 4,000 doses supplied by the Serum Institute of India.
WHO Declares Public Health Emergency
The World Health Organization declares the Bundibugyo Ebola outbreak in the DRC and Uganda a Public Health Emergency of International Concern (PHEIC), accelerating vaccine development and funding.
Meiji Seika Pharma will transfer manufacturing technology for its Japanese encephalitis vaccine, developed and marketed by KM Biologics in Japan, to Serum Institute of India. SII engineers have already visited Japan, and the Indian firm expects to file for regulatory approval as early as 2027.
Source: news.webindia123.com · aninews.in
A phase 1 trial of an adenovirus-vectored vaccine for the Bundibugyo Ebola strain is underway, enrolling 50 adults. With 620,000 doses pre-manufactured, the trial highlights rapid pandemic response but underscores immediate public health challenges as the outbreak’s death toll exceeds 700.
Source: deccanchronicle.com · seattletimes.com
